A Covid vaccine breakthrough bypasses the stale debate on patent waivers 

Heated debates have taken place at the WTO TRIPS Council over Covid-19 vaccine patents and IP rights, with ongoing discussions still taking place among diplomats from the US, India, South Africa, and the EU. For vaccine researchers, manufacturers, and public experts, though, the focus may have moved on some time ago, says Alan Beattie in a new “trade secrets” posting for the FT. Governments seem also to be shifting focus to emphasize practical efforts to extend  manufacturing and distribution capacity globally; by way of example, the EU recently announced a €1bn contribution to finance the German company BioNTech to set up a mobile vaccine manufacturing plant in Africa assembled from kits.

Read the full story.